Atrial fibrillation nursing: CHA₂DS₂-VASc scoring, cardioversion, and anticoagulation

Atrial fibrillation (AFib) is the most common sustained cardiac arrhythmia, affecting more than 6 million Americans and carrying a fivefold increased risk of ischemic stroke compared to patients in normal sinus rhythm. It is not simply a nuisance rhythm – it is a hemodynamic and thromboembolic threat that nurses in every setting will encounter. Med-surg patients develop new-onset AFib during sepsis and post-operatively. ICU patients with AFib in rapid ventricular response (RVR) deteriorate quickly. Outpatient AFib that goes undetected on a warfarin bridge leads to cardioembolic stroke. Understanding AFib – its mechanisms, its classifications, its treatment strategies, and its complications – is foundational nursing knowledge.

Key facts at a glance

This reference covers pathophysiology, AFib classification, rate vs rhythm control strategy, anticoagulation protocols including CHA₂DS₂-VASc scoring, cardioversion, acute nursing assessment and interventions, complications, and NCLEX-style questions. Pair it with the stroke nursing reference for cardioembolic stroke management and the EKG interpretation cheat sheet for rhythm identification.

Pathophysiology

Normal atrial conduction

Under normal conditions, the sinoatrial (SA) node fires at 60–100 times per minute, sending an organized electrical impulse across both atria simultaneously. This produces a discrete, upright P wave on the EKG and, critically, causes coordinated atrial contraction. That contraction squeezes approximately 20–30% of the final ventricular preload into the ventricle just before the mitral valve closes – a contribution called the atrial kick. In healthy hearts, the atrial kick adds roughly 15–30% to cardiac output. In patients with diastolic dysfunction, hypertrophic cardiomyopathy, or reduced ventricular compliance, the atrial kick may contribute up to 40–50% of forward flow.

Re-entry circuits and ectopic triggers

AFib is initiated by rapid, chaotic ectopic firing from multiple foci – most commonly from the ostia of the pulmonary veins as they enter the left atrium. These ectopic bursts bombard the atrial tissue at rates of 350–600 impulses per minute. The atrial tissue cannot depolarize and repolarize fast enough to follow each impulse as a coordinated wave; instead, multiple small re-entry circuits spin simultaneously across the atria in a disorganized pattern. The result is quivering atrial walls that produce no effective mechanical contraction – only a chaotic fibrillatory baseline (fine f waves) visible on EKG.

Atrial remodeling

Sustained AFib is not electrically neutral. Rapid, chaotic depolarization causes progressive structural and electrical changes in the atrial myocardium – a process called atrial remodeling. Calcium overload, oxidative stress, fibrosis, and altered ion channel expression all occur. These changes shorten atrial effective refractory periods, making the atrium increasingly vulnerable to re-initiating AFib whenever it terminates. This explains the well-known clinical observation: “AFib begets AFib.” The longer AFib persists, the harder it is to restore and maintain sinus rhythm.

AV node as a gatekeeper

The atrioventricular (AV) node receives the chaotic atrial impulses but is physiologically limited in how many it can conduct. Decremental conduction in the AV node means that impulses arriving too rapidly are blocked. The AV node passes approximately 100–170 impulses per minute to the ventricles in untreated AFib – this is “AFib with rapid ventricular response” (RVR). Importantly, even at this rate, the ventricular response is irregularly irregular because the timing of each conducted impulse is unpredictable. This produces the defining EKG pattern: no P waves, varying R-R intervals, and narrow QRS complexes (unless aberrant conduction is present).

Loss of atrial kick: hemodynamic consequences

When the atria fibrillate, coordinated atrial contraction is lost. The ventricles fill passively, and the 15–30% atrial kick contribution disappears. In patients with good ventricular function and low heart rates, this may be tolerated. In patients with:

• Diastolic dysfunction (hypertension, hypertrophic cardiomyopathy) – the ventricle is stiff and depends heavily on atrial filling; AFib causes marked CO reduction
• Rapid ventricular response – shortened diastolic filling time compounds the reduced preload
• Existing heart failure – already-compensated patients decompensate rapidly when AFib occurs

The clinical result ranges from mild palpitations and fatigue to pulmonary edema, hypotension, and cardiogenic shock, depending on the patient’s underlying cardiac reserve. See the heart failure nursing reference for the overlap between AFib and decompensated HF.

Left atrial appendage thrombus formation

With loss of coordinated atrial contraction, blood pools in the left atrial appendage (LAA) – a small, trabeculated, finger-shaped pouch off the lateral left atrium. This stagnant, turbulent flow creates ideal conditions for thrombus formation. Over 90% of cardioembolic thrombi in non-valvular AFib originate in the LAA. When a thrombus breaks loose, it enters the systemic circulation via the left ventricle. Because the carotid and cerebral arteries receive approximately 20% of cardiac output, emboli disproportionately travel to the brain – producing cardioembolic ischemic stroke. AFib accounts for approximately 15–20% of all ischemic strokes in the U.S. and for a higher proportion of severe, disabling strokes. This is the central reason why anticoagulation is the cornerstone of AFib management.

AFib classification

The ACC/AHA 2023 AFib guidelines classify AFib by duration and reversibility. Understanding these distinctions is critical because they drive treatment strategy – particularly the feasibility of cardioversion and rhythm control.

Valvular vs non-valvular AFib: An important sub-distinction affects anticoagulant choice. “Valvular AFib” historically referred to AFib in the setting of rheumatic mitral stenosis or mechanical prosthetic heart valves. These patients require warfarin – DOACs are not approved. “Non-valvular AFib” (the majority of cases) is where DOACs are preferred.

Rate control vs rhythm control

Two treatment philosophies govern AFib management. The choice between them depends on symptom burden, duration of AFib, age, cardiac function, and patient preference.

The EAST-AFNET 4 trial (2020) demonstrated that early rhythm control (initiated within 1 year of AFib diagnosis) reduced a composite of cardiovascular death, stroke, and hospitalization compared to rate control alone – representing a significant shift in guideline thinking toward earlier rhythm control in appropriate patients. The 2023 ACC/AHA guidelines now recommend early rhythm control as a Class IIa recommendation for many newly diagnosed AFib patients.

Rate control remains valid for patients with permanent AFib, those who fail or decline rhythm control, and older or high-risk patients where the benefit-risk balance of antiarrhythmics or ablation is unfavorable.

Anticoagulation

Why anticoagulation matters more than rhythm

A critical point that confuses many students: achieving sinus rhythm does not eliminate stroke risk. Patients in NSR after cardioversion can have asymptomatic AFib recurrences. The LAA may remain stunned (mechanically dysfunctional) even after sinus rhythm is restored. Anticoagulation decisions are made based on stroke risk score (CHA₂DS₂-VASc), not on whether the patient is currently in AFib.

CHA₂DS₂-VASc score

The CHA₂DS₂-VASc score quantifies annual stroke risk in non-valvular AFib and guides anticoagulation decisions. Higher scores indicate greater stroke risk and a stronger benefit from anticoagulation.

Anticoagulation thresholds (2023 ACC/AHA guidelines):

• Score ≥2 in men: oral anticoagulation recommended
• Score ≥3 in women: oral anticoagulation recommended
• Score 1 in men / Score 2 in women: anticoagulation may be considered; individualize based on bleeding risk
• Score 0 in men / Score 1 in women (female sex alone): anticoagulation not recommended

Annual stroke rates by score:

• Score 0: ~0.2% per year
• Score 1: ~0.6% per year
• Score 2: ~2.2% per year
• Score 3: ~3.2% per year
• Score 4: ~4% per year
• Score 5–6+: 6–12%+ per year

HAS-BLED – bleeding risk assessment

Before initiating anticoagulation, bleeding risk is assessed using the HAS-BLED score. A score ≥3 indicates high bleeding risk and warrants careful consideration, but it does not automatically contraindicate anticoagulation. High CHA₂DS₂-VASc scores generally outweigh bleeding risk – the goal is to identify and modify correctable bleeding risk factors (uncontrolled hypertension, excessive alcohol, concurrent NSAIDs).

HAS-BLED factors: Hypertension (uncontrolled, SBP >160), Abnormal renal or liver function (1 point each), Stroke (prior), Bleeding history or predisposition, Labile INR (time in therapeutic range <60%), Elderly (>65 years), Drugs (antiplatelets/NSAIDs) or alcohol (1 point each). Maximum 9 points.

Warfarin vs DOACs

DOACs vs warfarin – key summary: DOACs have predictable pharmacokinetics, fewer drug-food interactions, lower rates of intracranial hemorrhage, and do not require routine INR monitoring. They are the preferred choice for non-valvular AFib in most patients. Warfarin remains the standard for mechanical prosthetic heart valves, rheumatic mitral stenosis, and severe renal impairment where DOACs are contraindicated. See the nursing lab values cheat sheet for INR monitoring ranges and DVT nursing for broader anticoagulation principles in VTE.

EKG interpretation in AFib

AFib produces a distinctive and recognizable pattern on the 12-lead EKG or telemetry monitor. Students should be able to identify all four features confidently. For a broader rhythm interpretation framework, see the EKG interpretation cheat sheet.

Four hallmarks of AFib:

1. Irregularly irregular ventricular rhythm – R-R intervals vary from beat to beat with no discernible pattern. This is the most clinically important feature at the bedside (irregular pulse on palpation).
2. Absent P waves – No distinct, upright P wave precedes each QRS complex. Instead, the isoelectric baseline is replaced by chaotic, low-amplitude fibrillatory (f) waves, most visible in V1.
3. Fibrillatory baseline (f waves) – Rapid, disorganized undulations of the baseline at 350–600 per minute. Coarse f waves (larger amplitude) are more visible; fine f waves may be subtle or absent on the surface EKG.
4. Narrow QRS complex – Typically ≤120 ms, because ventricular conduction below the AV node is normal. Wide QRS complexes in AFib suggest aberrant conduction (bundle branch block, accessory pathway, or Wolff-Parkinson-White syndrome) or ventricular pacing.

AFib vs flutter: Atrial flutter produces regular, sawtooth flutter waves at approximately 300 bpm with a regular ventricular response (often 2:1, 3:1, or 4:1 block). AFib is distinguished by its irregular ventricular rate and absent discrete P waves.

Acute nursing assessment

Hemodynamic monitoring

When a patient presents with AFib or develops new-onset AFib, rapid assessment priorities include:

Immediate assessment (first 2–5 minutes):

• Vital signs: heart rate (rate and regularity), blood pressure, SpO₂, respiratory rate
• Symptoms: palpitations, dyspnea, chest pain, lightheadedness, syncope
• Level of consciousness: confusion or altered mentation suggests reduced cerebral perfusion
• If hemodynamically unstable (SBP <90 mmHg, altered consciousness, severe chest pain, signs of shock): immediate synchronized cardioversion – do not delay for anticoagulation

Signs of hemodynamic instability requiring urgent intervention:

• SBP <90 mmHg or MAP <65 mmHg
• Altered mental status
• Active chest pain (ischemic)
• Pulmonary edema (frothy sputum, severe dyspnea, SpO₂ <90% despite supplemental O₂)
• Signs of shock: mottling, cool extremities, diaphoresis

Rhythm interpretation at the bedside

The bedside assessment begins with pulse palpation. An irregularly irregular pulse – where no pattern of regularity can be detected – is the clinical hallmark of AFib. This contrasts with a regularly irregular pulse (e.g., bigeminy) or simply a fast irregular rate.

Confirm with telemetry or 12-lead EKG. Document:

• Ventricular rate (average rate on EKG strip)
• Presence or absence of P waves
• QRS width (narrow vs wide)
• Any signs of ischemia (ST changes, T-wave inversions)

Determining onset: the 48-hour rule

Establish the time of AFib onset as precisely as possible:

• Known onset <48 hours: Lower thrombus formation risk; cardioversion may proceed with anticoagulation initiated before or at the time of cardioversion
• Known onset >48 hours or unknown onset: Assume high thrombus risk; require either 3+ weeks of therapeutic anticoagulation before cardioversion OR transesophageal echocardiogram (TEE) to exclude LAA thrombus

Why 48 hours? Thrombus formation in the LAA begins after approximately 48 hours of continuous AFib. Within this window, the risk of cardioversion-related thromboembolism is low if anticoagulation is initiated promptly.

New-onset vs known AFib

Cardioversion

Cardioversion is the process of terminating AFib and restoring sinus rhythm. It can be achieved electrically or pharmacologically.

Electrical cardioversion (synchronized cardioversion)

Synchronized cardioversion delivers a direct current shock timed to the R wave (QRS complex), avoiding the T wave (the vulnerable period where unsynchronized shocks can precipitate ventricular fibrillation). It is the most reliable method for converting AFib to sinus rhythm.

Indications:

• Hemodynamically unstable AFib (immediate, regardless of anticoagulation status)
• Stable AFib where rhythm control is the chosen strategy

Pre-cardioversion checklist (stable, elective):

1. Confirm anticoagulation adequate – ≥3 weeks therapeutic warfarin (INR 2–3) or DOAC, OR TEE negative for LAA thrombus
2. Ensure IV access, cardiac monitoring, and crash cart availability
3. Obtain informed consent
4. NPO status for sedation (typically ≥4–6 hours for elective procedure)
5. Prepare for conscious sedation (propofol, midazolam, or etomidate per protocol)
6. Confirm synchronized mode is selected on the defibrillator – verify “SYNC” indicator is active
7. Apply conductive pads (anterior-posterior position preferred for AFib)
8. Administer sedation, confirm adequate sedation level before shock delivery
9. Deliver shock; confirm rhythm change on monitor

Energy levels:

• Biphasic defibrillator: 120–200 J initial dose (higher initial energy associated with higher first-shock success rates for AFib)
• Monophasic defibrillator: 200 J initial dose
• If first shock unsuccessful: escalate energy with successive attempts

Post-cardioversion nursing care:

• Monitor rhythm continuously for ≥4 hours post-procedure
• Assess vital signs every 15 minutes for 1 hour, then per protocol
• Monitor for skin burns at pad sites
• Continue anticoagulation for at least 4 weeks post-cardioversion (LAA stunning)
• Monitor for thromboembolic events (neurological changes, limb ischemia)

Nursing priority: Always verify synchronized mode before cardioversion. An unsynchronized shock during AFib (which becomes defibrillation) can precipitate VF. The sync marker should appear on the R waves on the monitor screen.

Pharmacological cardioversion

Drug-based rhythm conversion is an alternative for stable AFib of short duration (<48 hours), particularly when the patient refuses or is unsuitable for electrical cardioversion.

Rate control medications

Rate control is first-line for most patients and the sole strategy for those with permanent AFib. The target resting heart rate is <110 bpm (lenient control, evidence-based from RACE II trial) for most patients; <80 bpm (strict control) is used for symptomatic patients who remain symptomatic at rates 80–110.

Nursing interventions

Complications

Ischemic stroke and systemic embolism

The most feared complication of AFib is cardioembolic ischemic stroke. Compared to patients in sinus rhythm, patients with AFib have a fivefold increased risk of stroke. AFib-related strokes tend to be more severe and more disabling than atherothrombotic strokes – large LAA thrombi embolize to large cerebral vessels, producing large-territory infarcts with high morbidity. Approximately 15–20% of all ischemic strokes in the U.S. are attributable to AFib. Systemic embolism can also affect the mesenteric arteries (bowel ischemia), renal arteries, and peripheral arteries (acute limb ischemia). See the stroke nursing reference for acute stroke assessment and management.

Heart failure exacerbation

AFib and heart failure have a bidirectional relationship. AFib causes HF through multiple mechanisms: loss of atrial kick (reducing preload), rapid rate (shortening diastolic filling time and increasing myocardial oxygen demand), and irregular rhythm (reducing cardiac efficiency). Conversely, the structural changes of HF – elevated filling pressures, atrial dilation, and neurohormonal activation – create a substrate for AFib. When AFib develops in a compensated HF patient, decompensation can be rapid. See the heart failure nursing reference for HF management principles. Nursing assessment should include daily weights, fluid balance, lung sounds, and JVD monitoring in AFib patients with known HF.

Tachycardia-induced cardiomyopathy

Sustained rapid ventricular rates – typically >100–110 bpm for weeks to months – can cause tachycardia-induced cardiomyopathy (TIC): a reversible form of dilated cardiomyopathy resulting from chronic myocardial fatigue and energy depletion. Left ventricular ejection fraction (EF) falls, and the clinical picture resembles HF with reduced EF. The key distinguishing feature is that TIC is potentially reversible: adequate rate or rhythm control often leads to significant or complete EF recovery over weeks to months. This is why aggressive rate control in AFib with rapid response matters – it may prevent or reverse cardiomyopathy.

Hemodynamic instability and cardiogenic shock

In patients with severely compromised cardiac reserve, rapid AFib can precipitate cardiogenic shock. This is most common in patients with severe mitral stenosis (who depend almost entirely on atrial kick and controlled rate), hypertrophic obstructive cardiomyopathy (HOCM), or critical aortic stenosis. These patients require emergent cardioversion rather than pharmacological rate control, which may be inadequate or dangerously slow to achieve.

Cognitive decline and dementia

Emerging evidence suggests AFib is associated with accelerated cognitive decline and increased dementia risk, independent of clinical stroke – likely related to subclinical cerebral microemboli and reduced cerebral perfusion. This underscores the importance of anticoagulation beyond preventing clinically apparent stroke.

Patient education

Effective patient education is critical to AFib management. Poor anticoagulation adherence is the primary modifiable driver of AFib-related stroke. Key teaching points:

Anticoagulation compliance:

• Explain why anticoagulation matters: “The medication prevents blood clots from forming in your heart and traveling to your brain.”
• For warfarin patients: consistent dietary vitamin K intake (do not avoid leafy greens entirely – maintain consistent intake); attend all INR check appointments; never start or stop medications without provider knowledge (dozens of drugs affect INR); carry a medication card or wear a medical alert bracelet.
• For DOAC patients: never miss a dose; do not double-dose if a dose is missed; store medication away from heat and humidity; take rivaroxaban with the evening meal (absorption-dependent).

When to seek emergency care:

• Symptoms of stroke: sudden facial droop, arm weakness, speech difficulty, sudden severe headache, vision loss – call 911 immediately
• Severe dyspnea or sudden chest pain at rest
• Syncope or near-syncope
• Rapid or irregular heartbeat with dizziness or hemodynamic symptoms
• Signs of serious bleeding: blood in urine or stool, unusually heavy menstrual bleeding, coughing blood, vomiting blood

Rate and rhythm medications:

• Explain that heart rate medications are taken daily even when feeling well – they prevent the rate from becoming dangerously fast
• Do not stop rate-control medications abruptly (rebound tachycardia, especially with beta blockers)
• Antiarrhythmic drugs require consistent timing and should not be missed

Lifestyle modifications:

• Alcohol: even moderate alcohol consumption is a well-established AFib trigger; abstinence or strict moderation is recommended
• Sleep apnea: untreated OSA is a major, modifiable AFib risk factor; CPAP adherence reduces AFib recurrence
• Weight loss: obesity is an independent AFib risk factor; even modest weight reduction improves rhythm control outcomes
• Exercise: moderate aerobic exercise is beneficial; very high-intensity or long-duration endurance exercise can paradoxically increase AFib risk in some patients
• Hypertension control: BP below 130/80 mmHg recommended; hypertension is the most common modifiable AFib risk factor

Activity:

• Most AFib patients can maintain normal activity with rate control; palpitations during exertion should be reported
• Patients on anticoagulation should minimize contact sports and activities with fall risk; report all falls and injuries

NCLEX-style questions

Question 1

A nurse is caring for a patient with known atrial fibrillation who has not taken warfarin for three weeks. The patient now presents for elective electrical cardioversion. The physician wishes to proceed with cardioversion today. What is the nurse’s priority action?

A. Prepare the defibrillator in asynchronous mode B. Notify the physician that a TEE or 3-week therapeutic anticoagulation is required before elective cardioversion C. Administer IV metoprolol to slow the rate before cardioversion D. Obtain informed consent and proceed with cardioversion as ordered

Question 2

A nurse is assessing a 72-year-old male patient with newly diagnosed AFib. He has a history of hypertension, type 2 diabetes, and a prior ischemic stroke 2 years ago. What is his CHA₂DS₂-VASc score, and what does this indicate about anticoagulation?

A. Score 3 – anticoagulation is optional B. Score 5 – anticoagulation is strongly recommended C. Score 4 – anticoagulation decision should be deferred to cardiology D. Score 2 – anticoagulation is not indicated in males with score <2

Question 3

A nurse is preparing to administer IV diltiazem to a patient in AFib with rapid ventricular response (rate 158 bpm). Review of the medical record shows the patient received IV metoprolol 5 mg 20 minutes ago and the rate only decreased to 158. What should the nurse do?

A. Administer the diltiazem as ordered – the rate remains elevated and rate control is the priority B. Hold the diltiazem and notify the provider – concurrent IV beta blocker and IV CCB administration carries severe hemodynamic risk C. Administer diltiazem at half the ordered dose to minimize risk D. Administer diltiazem only if the patient’s blood pressure is above 120/80 mmHg

Question 4

A patient on digoxin for AFib rate control develops nausea, vomiting, and sees yellow-green halos around lights. Their potassium is 3.0 mEq/L. What is the nurse’s priority action?

A. Administer the next scheduled dose of digoxin and monitor symptoms B. Hold digoxin, notify the provider, monitor telemetry, and prepare to address the hypokalemia C. Administer IV potassium at 20 mEq/hour immediately D. Request a 12-lead EKG and proceed with scheduled digoxin dose if no arrhythmia is visible

Question 5

Which patient with atrial fibrillation is the best candidate for a rate-control rather than rhythm-control strategy?

A. A 45-year-old with paroxysmal AFib, symptomatic palpitations, and preserved EF B. A 68-year-old with permanent AFib, no symptoms at a rate of 85 bpm C. A 55-year-old with new-onset AFib found to be driving heart failure with reduced EF D. A 40-year-old competitive athlete with first-episode AFib

Question 6

A patient with AFib is being discharged on apixaban (Eliquis) 5 mg twice daily for stroke prevention. Which patient statement indicates that additional teaching is needed?

A. “I should take this medication every 12 hours, even if I feel fine.” B. “I don’t need to get blood tests every month like I did on warfarin.” C. “If I miss a dose, I should take two doses the next morning to make up for it.” D. “I should tell my dentist I’m on a blood thinner before any procedures.”

NANDA-I nursing care plans for atrial fibrillation

The following care plans address the five most clinically significant nursing diagnoses in atrial fibrillation. Each is grounded in the 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation and current NCLEX standards. Interventions and rationales are AF-specific – generic language has been avoided deliberately.

1. Decreased cardiac output

NANDA-I label: Decreased cardiac output (Domain 4: Activity/rest, Class 4: Cardiovascular/pulmonary responses)

Related to: Irregular ventricular rhythm secondary to chaotic atrial electrical activity and loss of coordinated atrial contraction

As evidenced by: Irregularly irregular pulse, reduced blood pressure, fatigue, dyspnea on exertion, or signs of pulmonary congestion

Assessment findings (AF-specific):

• Irregularly irregular pulse on palpation; heart rate variable beat to beat on telemetry with absent P waves
• Blood pressure lower than baseline; pulse pressure narrow if rapid ventricular response is reducing stroke volume
• Audible S3 or crackles at lung bases in patients with diastolic dysfunction, indicating impaired ventricular filling from loss of atrial kick

Nursing interventions:

Expected outcomes:

• Heart rate maintained at resting target <110 bpm (lenient control) within 4 hours of rate-control therapy initiation
• Blood pressure remains ≥90/60 mmHg and MAP ≥65 mmHg throughout hospitalization
• Patient reports improvement in dyspnea and fatigue as ventricular rate is controlled

2. Risk for ineffective cerebral tissue perfusion

NANDA-I label: Risk for ineffective cerebral tissue perfusion (Domain 4: Activity/rest, Class 4: Cardiovascular/pulmonary responses)

Related to: Thrombus formation in the left atrial appendage secondary to stagnant blood flow during atrial fibrillation, with potential for cardioembolism to cerebral vasculature

As evidenced by: Risk diagnosis – defining characteristics not present at time of assessment; presence of risk factors below

Assessment findings (AF-specific):

• CHA₂DS₂-VASc score ≥2 in men or ≥3 in women, indicating annual stroke risk ≥2.2% without anticoagulation
• New-onset or untreated AF of unknown duration or >48 hours, during which LAA thrombus may form
• Prior ischemic stroke or TIA in medical history, conferring 2 points on CHA₂DS₂-VASc and highest stroke risk subgroup

Nursing interventions:

Expected outcomes:

• Patient receives appropriate anticoagulation therapy consistent with their CHA₂DS₂-VASc score throughout hospitalization and at discharge
• No new neurological deficits develop during hospitalization
• Patient and family accurately describe three warning signs of stroke and the action to take before discharge

3. Activity intolerance

NANDA-I label: Activity intolerance (Domain 4: Activity/rest, Class 2: Activity/exercise)

Related to: Irregular cardiac rhythm and reduced cardiac output secondary to loss of atrial kick and variable ventricular filling

As evidenced by: Reports of fatigue and dyspnea with exertion, heart rate disproportionate to activity level, oxygen desaturation with minimal movement, or patient’s verbal report of inability to perform usual activities

Assessment findings (AF-specific):

• Exertional dyspnea at lower activity levels than baseline; patients with underlying diastolic dysfunction particularly affected because their ventricle depends on atrial kick for adequate filling
• Heart rate increases disproportionately with minimal activity (e.g., rising to 140–160 bpm with standing in a patient with AF with RVR), as the ventricular rate in AF is largely unregulated during sympathetic stimulation
• Fatigue and reduced exercise tolerance consistent with reduced cardiac output – estimated 15–30% CO reduction from loss of atrial kick, increasing to 40–50% in patients with diastolic dysfunction

Nursing interventions:

Expected outcomes:

• Patient tolerates progressive ambulation without heart rate exceeding 130 bpm or SpO₂ dropping below 93% during the activity period
• Patient reports reduction in exertional dyspnea as rate control is established within 24–48 hours of treatment initiation
• Patient accurately describes two activity warning signs requiring rest and provider notification before discharge

4. Risk for bleeding

NANDA-I label: Risk for bleeding (Domain 11: Safety/protection, Class 2: Physical injury)

Related to: Anticoagulation therapy (DOAC or warfarin) required for stroke prevention in atrial fibrillation

As evidenced by: Risk diagnosis – defining characteristics not present at time of assessment; presence of risk factors below

Assessment findings (AF-specific):

• HAS-BLED score ≥3, indicating high bleeding risk (uncontrolled hypertension, abnormal renal or liver function, prior stroke, bleeding history, labile INR, age >65, concurrent antiplatelet/NSAID use or alcohol)
• Concurrent antiplatelet therapy (aspirin, clopidogrel) prescribed in addition to anticoagulation, substantially increasing bleeding risk without proportional stroke-reduction benefit in most AF patients
• Warfarin with labile INR or time in therapeutic range (TTR) <60%, indicating sub-therapeutic or supratherapeutic anticoagulation and risk for both thrombosis and hemorrhage

Nursing interventions:

Expected outcomes:

• Patient remains free from clinically significant bleeding episodes throughout hospitalization
• INR maintained within therapeutic range (2.0–3.0) on warfarin, or DOAC taken at prescribed dose and interval without omissions
• Patient accurately describes three bleeding precautions and states when to seek emergency care before discharge

5. Deficient knowledge

NANDA-I label: Deficient knowledge (Domain 5: Perception/cognition, Class 4: Cognition)

Related to: New AF diagnosis and unfamiliarity with anticoagulation therapy, rate or rhythm control medications, and the long-term nature of stroke risk in AF

As evidenced by: Patient or family unable to explain what AF is, why anticoagulation is required, what symptoms require emergency care, or how to correctly take prescribed medications

Assessment findings (AF-specific):

• Patient newly diagnosed with AF, with no prior exposure to the condition, CHA₂DS₂-VASc scoring, or DOAC therapy; common misconception that restored sinus rhythm eliminates the need for anticoagulation
• Patient discharged on warfarin without understanding INR monitoring frequency, dietary vitamin K consistency requirements, or the extensive drug-interaction profile
• Patient unable to describe the symptoms of stroke or when to call 911, despite AF carrying fivefold increased stroke risk

Nursing interventions:

Expected outcomes:

• Patient accurately explains in their own words what AF is, why anticoagulation is required, and what triggers should prompt calling 911 before discharge
• Patient demonstrates correct medication technique (DOAC timing or warfarin INR monitoring plan) via teach-back before discharge
• Patient and at least one family member identify all five FAST stroke warning signs correctly

Frequently asked questions

What is the priority NANDA-I nursing diagnosis for atrial fibrillation?

The priority NANDA-I diagnosis for AF is Decreased cardiac output related to irregular ventricular rhythm. The irregular, often rapid ventricular response eliminates coordinated atrial contraction and reduces cardiac output by 15–30% (up to 40–50% in patients with diastolic dysfunction). This diagnosis takes precedence because hemodynamic compromise from rapid AF can progress to pulmonary edema or cardiogenic shock if rate control is not established promptly. In patients with known or suspected stroke, Risk for ineffective cerebral tissue perfusion becomes co-priority.

What are the key nursing interventions for atrial fibrillation?

Core AF nursing interventions include: continuous telemetry monitoring with documentation of rate and rhythm; hemodynamic assessment for signs of instability (SBP <90 mmHg, altered mentation, severe dyspnea); administration and monitoring of rate-control agents while holding for HR <60 or SBP <90 mmHg; confirmation that anticoagulation is ordered and administered to prevent LAA thrombus formation; baseline neurological assessment with FAST screening each shift; patient education on anticoagulation, stroke warning signs, and medication compliance. For unstable patients, preparation for synchronized cardioversion supersedes all pharmacological measures.

What are the signs of hemodynamic instability in AF?

Hemodynamic instability in AF is defined by any combination of: systolic blood pressure <90 mmHg or MAP <65 mmHg; altered level of consciousness or acute confusion; severe chest pain or evidence of active myocardial ischemia; acute pulmonary edema (frothy sputum, SpO₂ <90% despite supplemental oxygen, severe dyspnea); or signs of shock (mottling, cool and clammy extremities, diaphoresis). These findings indicate inadequate cardiac output from uncontrolled AF and require immediate synchronized cardioversion – pharmacological rate control is too slow and may worsen hemodynamics.

Why does AF require anticoagulation even after cardioversion?

Successful cardioversion to sinus rhythm does not eliminate stroke risk for two reasons. First, the left atrial appendage often remains mechanically stunned for 2–4 weeks after cardioversion, during which thrombi can still form even though the rhythm appears normal on EKG. Second, most patients have asymptomatic AF recurrences after cardioversion that go undetected. Anticoagulation decisions are governed by the patient’s CHA₂DS₂-VASc score, not by their current rhythm. Guidelines recommend continuing anticoagulation for at least 4 weeks post-cardioversion in all patients, and indefinitely in those with CHA₂DS₂-VASc ≥2 in men or ≥3 in women.

What is the difference between rate control and rhythm control in AF?

Rate control accepts the AF rhythm and focuses on slowing the ventricular response to <110 bpm (lenient) or <80 bpm (strict) using beta blockers, non-dihydropyridine calcium channel blockers, or digoxin. Rhythm control attempts to restore and maintain normal sinus rhythm using electrical cardioversion, pharmacological cardioversion (ibutilide, flecainide, amiodarone), antiarrhythmic drugs, or catheter ablation. Rate control is preferred for older patients, permanent AF, and those with minimal symptoms. Rhythm control is favored for younger patients, symptomatic AF, or cases where AF is driving heart failure. Both strategies require anticoagulation based on CHA₂DS₂-VASc score – neither approach eliminates stroke risk independently.

When should a nurse hold digoxin in AF?

Hold digoxin and notify the provider for: heart rate <60 bpm (digoxin slows AV nodal conduction, and further slowing risks complete heart block); serum digoxin level above the therapeutic range (0.5–0.9 ng/mL for rate control in AF); hypokalemia (potassium <3.5 mEq/L – hypokalemia potentiates digoxin binding to cardiac Na⁺/K⁺-ATPase, dramatically increasing toxicity risk); or any sign of digoxin toxicity (nausea, vomiting, anorexia, yellow-green visual halos, bradycardia, or any new arrhythmia on telemetry). Digoxin toxicity is life-threatening; the priority actions are to hold the drug, notify the provider, obtain a digoxin level and electrolytes, and place the patient on continuous cardiac monitoring.

What is AF with RVR and what is the nursing priority?

AF with rapid ventricular response (RVR) is AF with a ventricular rate typically >100–110 bpm. At these rates, diastolic filling time is shortened, cardiac output falls, and myocardial oxygen demand increases. The nursing priority is to assess hemodynamic stability first: for any patient with SBP <90 mmHg, altered consciousness, or severe respiratory distress, prepare immediately for synchronized cardioversion. For hemodynamically stable patients with RVR, administer ordered rate-control agents (IV metoprolol or diltiazem), monitor the response, and hold agents that cause further hypotension or bradycardia. Identify and treat precipitating causes (infection, pain, hypoxia, dehydration, medication non-compliance) as these are often the driver of the rate escalation.

What are the nursing considerations for cardioversion in AF?

Before elective cardioversion: verify adequate anticoagulation (≥3 weeks therapeutic warfarin with INR 2–3, or full-dose DOAC, or TEE negative for LAA thrombus); ensure IV access, crash cart availability, and defibrillator is in synchronized mode with sync markers visible on R waves; confirm NPO status and sedation availability. During: apply pads in anterior-posterior position; deliver shock at 120–200 J biphasic; escalate energy if initial shock fails. After: monitor continuously for ≥4 hours; assess for skin burns at pad sites; continue anticoagulation for at least 4 weeks (LAA stunning); monitor for thromboembolic events (sudden neurological changes, limb ischemia). The single most critical safety check is verifying synchronized mode – an unsynchronized shock in AF can precipitate ventricular fibrillation.

References

1. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for diagnosis and management of atrial fibrillation. J Am Coll Cardiol. 2024;83(1):109–279. doi:10.1016/j.jacc.2023.08.017
2. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):104–132. doi:10.1016/j.jacc.2019.01.011
3. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
4. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi:10.1378/chest.09-1584
5. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138(5):1093–1100. doi:10.1378/chest.10-0134
6. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation (update). Eur Heart J. 2024;45(36):3645–3731. doi:10.1093/eurheartj/ehae176
7. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation (EAST-AFNET 4 trial). N Engl J Med. 2020;383(14):1305–1316. doi:10.1056/NEJMoa2019422
8. American Heart Association. About atrial fibrillation (AFib or AF). Updated 2023. https://www.heart.org/en/health-topics/atrial-fibrillation
9. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation (RACE II trial). N Engl J Med. 2010;362(15):1363–1373. doi:10.1056/NEJMoa1001337
10. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation (AFFIRM trial). N Engl J Med. 2002;347(23):1825–1833. doi:10.1056/NEJMoa021328
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY trial). N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa0905561
12. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE trial). N Engl J Med. 2011;365(11):981–992. doi:10.1056/NEJMoa1107039
13. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF trial). N Engl J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa1009638
14. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659–666. doi:10.1056/NEJM199809033391003
15. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429. doi:10.1093/eurheartj/ehq278